AIMS: We compared two prospective trials of intra-arterial cytokine/chemotherapeutic infusion plus chemoembolization in the treatment of inoperable @entity14 . MATERIALS AND METHODS: One hundred and three @entity1 with disseminated inoperable @entity14 received intra-arterial chemotherapy with @entity1487 and @entity2841 ( @entity2841 ) plus chemoembolization via an angiographically positioned hepatic artery catheter. Two different regimens were used in two consecutive studies. Group A: short-term i.a. infusion of 550 mg/m(2) @entity1487 (days 1-4) plus 80 microg/m(2) @entity2841 (day 1+2) combined with chemoembolization with 25 mg/m(2)melphalan plus @entity4831 and Gelfoam (day 5). Group B: continuous circadian intra-arterially administered 1400 mg/m(2) @entity1487 infusion plus 60 mg/m(2)i.v. leucovorin and 80 microg/m(2) @entity2841 (day 1+2) combined with chemoembolization with 25 mg/m(2)melphalan plus @entity4831 and Gelfoam (day 3). RESULTS: One hundred and three @entity1 (62 male/41 female) with a median age of 59.9 and a median Karnofsky index of 88.5 were treated with 447 cycles of immuno-chemoembolization (group A 299, group B 148 cycles). Fifty-seven percent of these @entity1 had received prior systemic chemotherapy. Side-effects were seen in all @entity1 , mainly upper @entity490 lasting 1-4 days and grade 1 or 2 @entity391 . Systemic side-effects were mild and transient with a very low rate of @entity1431 . Using World Health Organization response criteria, the following responses could be demonstrated: group A: CR 2.7%, PR 32.4%, MR 21.6%, SD 12.7%, NR 16.2%; group B: CR 1.0%, PR 42.4%, MR 24.2%, SD 18.2%, NR 12.1%. Time to progression was 7 as compared to 8 months. Median survival was 17 months in group A, whereas it has not been reached after 28 months (P=0.0095) in group B. There was no statistically significant difference between chemo-naive @entity1 and @entity1 who had received prior systemic therapy. CONCLUSION: Immuno-chemoembolization combined with 2-day circadian administration of @entity1487 is an effective tool in the treatment of disseminated @entity14 . This regimen is also effective as second-line treatment.

Intra-arterial infusion of @entity1487 plus @entity2841 ( XXXX ) and chemoembolization with melphalan in the treatment of disseminated @entity14 .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity391 :: ('MESH:D014839', 'Disease') :: ['vomiting'] @entity4831 :: ('MESH:D004998', 'Chemical') :: ['Lipiodol'] @entity1431 :: ('MESH:D007970', 'Disease') :: ['leukopenia'] @entity14 :: ('MESH:D015179', 'Disease') :: ['colorectal liver metastases'] @entity490 :: ('MESH:D015746', 'Disease') :: ['abdominal pain'] @entity2841 :: ('1437', 'Gene') :: ['granulocyte-macrophage colony-stimulating factor', 'GM-CSF'] @entity1487 :: ('MESH:D005472', 'Chemical') :: ['5-FU']
@entity2841 :: (1437,Gene) :: ['GM-CSF']
